Jai Health plans heart disease biomarker test launch; Leicester Uni gets £7M biomarker investment;

> Indian company Jai Health is planning a launch of its genetic biomarker-based test to assess the risk of heart disease. Article

> The University of Leicester (U.K.) has received a £7 million ($11 million) donation to build a new biomarker facility. Press release | Article

> Genetic variants behind melanoma could affect how patients respond to Plexxikon and Roche's ($RHHBY) Zelboraf (vemurafenib). Press release | Abstract

> Chromosomal aberrations could point the way to personalized care, according to a review from the University of Colorado Cancer Center. Abstract | Blog post

> Plasma osteopontin marks prostate cancer aggression, risk and treatment response. Abstract

> Urine podocin:nephrin mRNA ratio could be a useful marker in kidney disease. Abstract

> Antigen Discovery gets a Phase II SBIR grant to find biomarkers linked with protection against malaria. Press release

> Researchers find three more diabetes markers. Article

> Boston diagnostics company Immunetics has received $629,000 in equity for the commercialization of a blood platelet contamination tester for hospitals and blood banks. Article

> Norwegian biotech and biopharma company BerGenBio has appointed former KuDOS CEO Barrie Ward to its board. Press release

And Finally… Speech patterns can be used as a marker for both depression severity and response to treatment, according to a U.S. and Australian research project. Abstract | Press release

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.